Solid Tumor Manufacturers, Suppliers & Companies
-
Manufacturerbased in Cambridge, MASSACHUSETTS (USA)
At Rubius Therapeutics, we are ushering in a new era in cellular medicine—an era in which we aim to transform the treatment of cancer and autoimmune diseases. Built upon the discoveries of Professors Harvey Lodish and Hidde Ploegh of the Whitehead ...
Rubius Therapeutics - Model RTX-240 - Treatment of Advanced Solid Tumors
Study Title: Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors. Status: ...
CONTACT SUPPLIER -
Technologybased in Rockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
Model C-CAR036 - Solid Tumors
PRODUCT: C-CAR036. INDICATION: Solid Tumor. PLATFORM: CAR-T. PRECLINICAL: Claudin 18.2. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
CONTACT SUPPLIER -
Software vendorbased in Boston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries.  Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
SOPHiA - Version DDM - Cloud-Based Software Platform for Solid Tumors
Genomic profiling is driving precision oncology. From targeted to comprehensive solutions, Next-Generation-Sequencing (NGS) offers the capacity to simultaneously analyze a select set of genes, regions, and biomarkers based on known ...
CONTACT SUPPLIER -
Service providerbased in Astoria, NEW YORK (USA)
We develop immune system modulators that activate and direct the most powerful immune cells in the body for targeted responses to disease. Our underpinning science originates from two of New Zealand’s leading research institutes, the Ferrier ...
Avalia - Treatment Therapy for Solid Tumors
Avalia’s solid tumor preclinical program focusing on eradication of solid tumors has shown meaningful tumor regression and survival benefits in models of ...
CONTACT SUPPLIER -
Manufacturerbased in Brisbane, CALIFORNIA (USA)
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer. Our lead therapy is AO-176, an anti-CD47 antibody ...
Arch - Model AO-176 - Antibody for Cancer
We are advancing our pipeline of antibodies for the treatment of patients with cancer. AO-176 is a highly differentiated anti-CD47 IgG2 antibody currently in clinical trials for solid tumors and multiple myeloma. ...
CONTACT SUPPLIER -
Manufacturerbased in Carlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
Model RAS-F - RAS Protein Inhibitors as Treatments for Advanced Solid Tumors
, and differentiation (see figure). RAS itself acts as a “hub” that activates multiple effector pathways and blocking any single pathway is ineffective for many tumor types, including pancreatic, lung, and colorectal ...
CONTACT SUPPLIER -
Technologybased in Berkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
CAR-NK - Cell Therapies for Solid Tumors
Natural killer (NK) cells, as their name implies, play an important role in ridding the body of cancer and viruses. NK cells are emerging as an increasingly important cell type for therapeutic development. Solid ...
CONTACT SUPPLIER -
Technologybased in Vancouver, BRITISH COLUMBIA (CANADA)
Canexia Health (formerly Contextual Genomics) makes high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support. Our genomics-based oncology solutions are designed to advance ...
Fusions - Partner-Agnostic Method Solutions in Solid Tumors
Gene fusions are the result of other genomic events, such as translocation, interstitial deletion, or chromosomal inversion. Gene fusions are known to be driver mutations in many different tumors and more recently, have emerged as ...
CONTACT SUPPLIER -
Manufacturerbased in Berlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
Model TK-8001 - TCR-T Targeting MAGE-A1 Positive Solid Tumors
the high unmet need in MAGE-A1 expressing cancers, no reported protein expression in healthy tissues other than testis and significant consistency of expression between the primary tumor and metastases. As high affinity TCRs ...
CONTACT SUPPLIER -
Technologybased in Pasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Model LB-100 - Hematologic and Solid Tumor Cancers
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid ...
CONTACT SUPPLIER -
Manufacturerbased in Philadelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Adaptimmune - Model ADP-A2M4 (MAGE-A4) - Spear T-Cell Therapy
Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly ...
CONTACT SUPPLIER -
Manufacturerbased in Sherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
T-Cure - Model 806TCR - HLA-A2 Haplotype
Using its iSORT platform, T-Cure identified 806TCR, an NY-ESO-1-specific TCR restricted to HLA-A2 haplotype. The 806TCR is in IND-enabling studies. NY-ESO-1 has been demonstrated clinically as a suitable target for TCR therapies for multiple ...
CONTACT SUPPLIER -
Manufacturerbased in Philadelphia, PENNSYLVANIA (USA)
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...
Context - Model CTIM-76 - Claudin 6 x CD3 Bispecific Antibody
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that ...
CONTACT SUPPLIER -
Manufacturerbased in Cambridge, MASSACHUSETTS (USA)
Obsidian Therapeutics is using its proprietary cytoDRiVE platform to harness the power of proteins to engineer precision medicines. Our lead internal programs are focused on engineering TIL therapies that are more effective and safer for patients ...
-
Technologybased in Basel, SWITZERLAND
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of ...
Proprietary Platform for Protein Delivery
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where ...
CONTACT SUPPLIER -
Technologybased in New York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
Stemline - Model SL-801 - Structurally Novel
SL-801 is a structurally novel, oral, small molecule, reversible inhibitor of exportin-1 (XPO1), a nuclear transport protein implicated in both solid tumors and hematologic malignancies. SL-801 has demonstrated ...
CONTACT SUPPLIER -
Manufacturerbased in Berkeley, CALIFORNIA (USA)
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies. Actym is also developing a broad pipeline of additional therapeutic candidates intended to treat checkpoint refractory ...
Actym - Biotechnology Pipeline Product
enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident antigen-presenting cells. ...
CONTACT SUPPLIER -
Manufacturerbased in Abingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
PsiOxus - Model T-SIGn - Viral Vector Platform Technology
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally ...
CONTACT SUPPLIER -
Manufacturerbased in Florence, ITALY
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, ...
Model SL-901 - Oral Small Molecule
SL-901 is an oral small molecule PI3K and DNA-PK inhibitor that has demonstrated activity against PI3K α/δ and PIK3C2 β. SL-901 has shown preclinical activity against a variety of tumor types. A Phase 1 trial in ...
CONTACT SUPPLIER -
Manufacturerbased in New York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
DeltEx Allo DRI - Model INB-400 - Glioblastoma Gamma-Delta T Cell Product
INB-400, our DeltEx Allo DRI, is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” ...
CONTACT SUPPLIER
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you